Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041274 · ClinicalTrials.gov registry record · Phase 4
DECIFER: Depression and Citalopram In First Episode Recovery
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT01041274 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 95 participants.
The verdict
NCT01041274, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients. Because depressive symptoms are common in first episode patients, we will test the hypothesis that adding the SSRI citalopram to a pre-established medication regimen will improve quality of life and decrease relapse and suicidality over the course of a 12-month trial.
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive Behavioral Therapy (CBT)
- BEHAVIORAL Psychoeducation
- DRUG Citalopram
- RADIATION Functional Magnetic Resonance Imaging (fMRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2010-01 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041274
The ClinicalTrials.gov registry entry for NCT01041274 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01041274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01041274 about?
NCT01041274 is a clinical study titled "DECIFER: Depression and Citalopram In First Episode Recovery". This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients. Because depressive symptoms are common in first episode patients, we will test the hyp...
What is the current status of trial NCT01041274?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2010-01. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT01041274?
The interventions under investigation include: Placebo (DRUG), Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Psychoeducation (BEHAVIORAL), Citalopram (DRUG), Functional Magnetic Resonance Imaging (fMRI) (RADIATION).
Who is sponsoring clinical trial NCT01041274?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.